Cardiovascular Diseases, COVID-19
Conditions
Keywords
COVID-19, myocardial injury
Brief summary
This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.
Detailed description
The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported to a growing number of countries. Recently, investigators have revealed that acute myocardial injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient outcomes. This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients.
Interventions
OTHERnon
no intervention
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* (1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3) Lung involvement confirmed with chest imaging.
Exclusion criteria
* No cTnI test on admission
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The myocardial injury incidence | 75 days | The myocardial injury incidence of COVID-19 patients |
| The risk factors analysis for the death | 75 days | The risk factors analysis for the death of COVID-19 patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics | 75 days | The clinical characteristics description of COVID-19 patients |
| Clinical course | 75 days | The clinical course description of COVID-19 patients |
| Cardiovascular comorbidity | 75 days | The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patients |
| Analysis of causes of death | 75 days | Analysis of causes of death in COVID-19 patients |
Countries
China
Outcome results
None listed